Wellcome Trust Centre for Gene Regulation and Expression

Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis

Retrieved on: 
Tuesday, May 31, 2022
Department, Physician, UC, Metabolism, Doctor of Philosophy, Private Securities Litigation Reform Act, Hospital, Journal, University of Oxford, DDW, Nasdaq, Ulcerative colitis, Endoscopy, Proteomics, Patient, Financial condition report, Result, Analysis, UZ Leuven, Therapy, National university, Serri, Sardinia, COVID-19, Genetics, Trial of the century, Research, IBD, McGill University, Gastroenterology, SAN, Industry, Prijs der Nederlandse Letteren, Montreal, University, KU Leuven, Safety, Montreal General Hospital, Gastrointestinal disease, Precision medicine, SEC, GI, MD, Wellcome Trust Centre for Gene Regulation and Expression, Annual report, GLOBE, Medical device, Medical imaging, Pharmaceutical industry, Medicine, Colitis

In the presentation, Dr. Vermiere presented patient data confirming a significant relationship between drug levels in tissue and endoscopic improvement in patients with moderate to severe ulcerative colitis (UC) who were treated with tofacitinib.

Key Points: 
  • In the presentation, Dr. Vermiere presented patient data confirming a significant relationship between drug levels in tissue and endoscopic improvement in patients with moderate to severe ulcerative colitis (UC) who were treated with tofacitinib.
  • This study supports the hypothesis that a tissue concentration of tofacitinib at or exceeding IC90 is directly correlated to significant improvement in patient outcomes, Adi Mohanty, Chief Executive Officer of Biora Therapeutics.
  • Our targeted delivery platform is uniquely positioned to be able to safely deliver the desired amount of drug to the diseased tissue in UC.
  • We recently also shared data about the potential importance of combination therapy for the UC patient community.

 Adrestia Appoints Human Genetics Leader, Professor John Perry, to Build Human Genetics Computational Platform

Retrieved on: 
Wednesday, May 18, 2022
Nursing, Biotechnology, Professional Services, Health, Pharmaceutical, Venture Capital, Other Science, Research, Genetics, Science, Clinical Trials, Department, Cancer, GSK, Atlas, Phenotype, Genome, Disease, Population, Wellcome Trust Centre for Gene Regulation and Expression, University, Gene, University of Exeter Medical School, Medical Research Council, Multimedia, Patient, Therapy, Obesity, MRC, Nature, Twin, University College London, Genetics, Cell, Research, Type 2 diabetes, Gurdon Institute, Lists of diseases, King's College London, Statistical genetics, Probability, Life, Center, Human, Publication, Associative group analysis, Drug development, Behavior, Mutation, UK Biobank, Drug discovery, Human genetics, Olaparib, Pharmaceutical industry, Antibiotics, Science, Adrasteia

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B.

Key Points: 
  • Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B.
  • Studying this genetic diversity in population studies gives us a hypothesis-free, genome wide screen for identifying and validating genes causing or influencing human disease.
  • Combining population genetics with Adrestias synthetic rescue platform provides unprecedented opportunities to efficiently unlock new ways of treating some of the worlds most intractable diseases.
  • Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new approaches to treating intractable genetic diseases.